Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Thursday, March 28, 2024 | Back issues
Courthouse News Service Courthouse News Service

Shareholder Class Action 

Shareholders say in a federal class action that they lost more than $100 million when Abbvie biopharmaceuticals announced it was buying back up to $7.5 billion of its own shares in a modified Dutch auction at $105 a share, but after the market closed, revealed that the price was only $103 a share.

CHICAGO — Shareholders say in a federal class action that they lost more than $100 million when Abbvie biopharmaceuticals announced it was buying back up to $7.5 billion of its own shares in a modified Dutch auction at $105 a share, but after the market closed, revealed that the price was only $103 a share.

Categories / Securities

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...